Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage

William D. Freeman, Thomas G Brott, Kevin M Barrett, Pablo R. Castillo, H. Gordon Deen, Leo F. Czervionke, James F Meschia

Research output: Contribution to journalArticle

177 Citations (Scopus)

Abstract

OBJECTIVE: To assess the effects of recombinant factor VIIa (rFVIIa) on hemorrhage volume and functional outcomes in warfarin-related acute intracranial hemorrhage (ICH), which has a 30-day mortality of more than 50%. PATIENTS AND METHODS: We reviewed the clinical, laboratory, and radiographic features of a consecutive series of 7 patients (median age, 87 years; 5 women) with symptomatic, nontraumatic warfarin-related acute ICH treated with intravenous rFVIIa at St. Luke's Hospital in Jacksonville, Fla, between December 2002 and September 2003. Prestroke baseline functional status was assessed with the modified Rankin Scale. Outcome was assessed with the Glasgow Outcome Scale. RESULTS: The International normalized ratio decreased from a mean of 2.7 before administration of rFVIIa to 1.08 after administration of rFVIIa. The median prestroke score on the modified Rankin Scale was zero. The median presenting score on the Glasgow Coma Scale was 14 (range, 4-15). The mean time from onset to treatment was 6.2 hours. The mean initial dose of rFVIIa was 62.1 μg/kg. One patient underwent placement of an external ventricular drain, and another underwent craniotomy and hematoma evacuation. Five of the 7 patients survived and were dismissed from the hospital with severe disability (Glasgow Outcome Scale, 3); 2 patients died during hospitalization. CONCLUSIONS: Intravenous bolus administration of rFVIIa can rapidly lower the international normalized ratio and appears to be safe for patients with warfarin-related ICH. Prospective controlled studies are needed to determine whether rFVIIa can prevent hematoma expansion and improve neurologic outcomes in patients with warfarin-related ICH.

Original languageEnglish (US)
Pages (from-to)1495-1500
Number of pages6
JournalMayo Clinic Proceedings
Volume79
Issue number12
StatePublished - 2004

Fingerprint

Intracranial Hemorrhages
Warfarin
Glasgow Outcome Scale
International Normalized Ratio
Hematoma
Glasgow Coma Scale
Craniotomy
recombinant FVIIa
Intravenous Administration
Nervous System
Hospitalization
Prospective Studies
Hemorrhage
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. / Freeman, William D.; Brott, Thomas G; Barrett, Kevin M; Castillo, Pablo R.; Deen, H. Gordon; Czervionke, Leo F.; Meschia, James F.

In: Mayo Clinic Proceedings, Vol. 79, No. 12, 2004, p. 1495-1500.

Research output: Contribution to journalArticle

Freeman, William D. ; Brott, Thomas G ; Barrett, Kevin M ; Castillo, Pablo R. ; Deen, H. Gordon ; Czervionke, Leo F. ; Meschia, James F. / Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. In: Mayo Clinic Proceedings. 2004 ; Vol. 79, No. 12. pp. 1495-1500.
@article{8c66f6a0506643a2bc032ee42a826f4d,
title = "Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage",
abstract = "OBJECTIVE: To assess the effects of recombinant factor VIIa (rFVIIa) on hemorrhage volume and functional outcomes in warfarin-related acute intracranial hemorrhage (ICH), which has a 30-day mortality of more than 50{\%}. PATIENTS AND METHODS: We reviewed the clinical, laboratory, and radiographic features of a consecutive series of 7 patients (median age, 87 years; 5 women) with symptomatic, nontraumatic warfarin-related acute ICH treated with intravenous rFVIIa at St. Luke's Hospital in Jacksonville, Fla, between December 2002 and September 2003. Prestroke baseline functional status was assessed with the modified Rankin Scale. Outcome was assessed with the Glasgow Outcome Scale. RESULTS: The International normalized ratio decreased from a mean of 2.7 before administration of rFVIIa to 1.08 after administration of rFVIIa. The median prestroke score on the modified Rankin Scale was zero. The median presenting score on the Glasgow Coma Scale was 14 (range, 4-15). The mean time from onset to treatment was 6.2 hours. The mean initial dose of rFVIIa was 62.1 μg/kg. One patient underwent placement of an external ventricular drain, and another underwent craniotomy and hematoma evacuation. Five of the 7 patients survived and were dismissed from the hospital with severe disability (Glasgow Outcome Scale, 3); 2 patients died during hospitalization. CONCLUSIONS: Intravenous bolus administration of rFVIIa can rapidly lower the international normalized ratio and appears to be safe for patients with warfarin-related ICH. Prospective controlled studies are needed to determine whether rFVIIa can prevent hematoma expansion and improve neurologic outcomes in patients with warfarin-related ICH.",
author = "Freeman, {William D.} and Brott, {Thomas G} and Barrett, {Kevin M} and Castillo, {Pablo R.} and Deen, {H. Gordon} and Czervionke, {Leo F.} and Meschia, {James F}",
year = "2004",
language = "English (US)",
volume = "79",
pages = "1495--1500",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "12",

}

TY - JOUR

T1 - Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage

AU - Freeman, William D.

AU - Brott, Thomas G

AU - Barrett, Kevin M

AU - Castillo, Pablo R.

AU - Deen, H. Gordon

AU - Czervionke, Leo F.

AU - Meschia, James F

PY - 2004

Y1 - 2004

N2 - OBJECTIVE: To assess the effects of recombinant factor VIIa (rFVIIa) on hemorrhage volume and functional outcomes in warfarin-related acute intracranial hemorrhage (ICH), which has a 30-day mortality of more than 50%. PATIENTS AND METHODS: We reviewed the clinical, laboratory, and radiographic features of a consecutive series of 7 patients (median age, 87 years; 5 women) with symptomatic, nontraumatic warfarin-related acute ICH treated with intravenous rFVIIa at St. Luke's Hospital in Jacksonville, Fla, between December 2002 and September 2003. Prestroke baseline functional status was assessed with the modified Rankin Scale. Outcome was assessed with the Glasgow Outcome Scale. RESULTS: The International normalized ratio decreased from a mean of 2.7 before administration of rFVIIa to 1.08 after administration of rFVIIa. The median prestroke score on the modified Rankin Scale was zero. The median presenting score on the Glasgow Coma Scale was 14 (range, 4-15). The mean time from onset to treatment was 6.2 hours. The mean initial dose of rFVIIa was 62.1 μg/kg. One patient underwent placement of an external ventricular drain, and another underwent craniotomy and hematoma evacuation. Five of the 7 patients survived and were dismissed from the hospital with severe disability (Glasgow Outcome Scale, 3); 2 patients died during hospitalization. CONCLUSIONS: Intravenous bolus administration of rFVIIa can rapidly lower the international normalized ratio and appears to be safe for patients with warfarin-related ICH. Prospective controlled studies are needed to determine whether rFVIIa can prevent hematoma expansion and improve neurologic outcomes in patients with warfarin-related ICH.

AB - OBJECTIVE: To assess the effects of recombinant factor VIIa (rFVIIa) on hemorrhage volume and functional outcomes in warfarin-related acute intracranial hemorrhage (ICH), which has a 30-day mortality of more than 50%. PATIENTS AND METHODS: We reviewed the clinical, laboratory, and radiographic features of a consecutive series of 7 patients (median age, 87 years; 5 women) with symptomatic, nontraumatic warfarin-related acute ICH treated with intravenous rFVIIa at St. Luke's Hospital in Jacksonville, Fla, between December 2002 and September 2003. Prestroke baseline functional status was assessed with the modified Rankin Scale. Outcome was assessed with the Glasgow Outcome Scale. RESULTS: The International normalized ratio decreased from a mean of 2.7 before administration of rFVIIa to 1.08 after administration of rFVIIa. The median prestroke score on the modified Rankin Scale was zero. The median presenting score on the Glasgow Coma Scale was 14 (range, 4-15). The mean time from onset to treatment was 6.2 hours. The mean initial dose of rFVIIa was 62.1 μg/kg. One patient underwent placement of an external ventricular drain, and another underwent craniotomy and hematoma evacuation. Five of the 7 patients survived and were dismissed from the hospital with severe disability (Glasgow Outcome Scale, 3); 2 patients died during hospitalization. CONCLUSIONS: Intravenous bolus administration of rFVIIa can rapidly lower the international normalized ratio and appears to be safe for patients with warfarin-related ICH. Prospective controlled studies are needed to determine whether rFVIIa can prevent hematoma expansion and improve neurologic outcomes in patients with warfarin-related ICH.

UR - http://www.scopus.com/inward/record.url?scp=9644254211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9644254211&partnerID=8YFLogxK

M3 - Article

C2 - 15595332

AN - SCOPUS:9644254211

VL - 79

SP - 1495

EP - 1500

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 12

ER -